MONTREAL, October 7, 2014 /PRNewswire/ --Updated
clinical trial data from REPLICor's three Asian trials using its
nucleic acid polymer (NAP) HBsAg-release inhibitors REP 2055 (REP 9AC)
and REP 2139 (REP 9AC') will be presented at the 10th Annual Meeting of the Oligonucleotide Society, to be held from Oct 12-16, 2014 in San Diego, CA.
REPLICor
has currently tested its HBsAg-release inhibitor technology in three
different clinical trials using different treatment modalities: in
monotherapy, in combination with short term immunotherapy and in
combination with a complete course of Pegasys™. Data presented will
demonstrate 1) the unique ability of REPLICor's NAP compounds to
completely suppress HBsAg in the blood 2) the effect of HBsAg clearance
on dramatically improving the activity of immunotherapy and 3) when used
with a full course of Pegasys™, NAP therapy has resulted in the
establishment of long term SVR in 80% of patients.
Link to the 2014 OTS meeting:
For more information please contact:
Andrew Vaillant, Ph.D.
Vice President, Operations and Chief Scientific Officer
Tel.: +1-514-862-2271
availlant@replicor.com
SOURCE Replicor Inc
Labels: REP 2055 (REP 9AC)